HilleVax Files 8-K on Shareholder Vote Matters
| Field | Detail |
|---|---|
| Company | Hillevax, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
HilleVax held a shareholder vote on 6/23, details to follow.
AI Summary
HilleVax, Inc. filed an 8-K on June 25, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 23, 2025. The filing does not provide details on the specific matters voted upon or the outcome.
Why It Matters
This filing indicates that HilleVax, Inc. held a shareholder vote, which could pertain to significant corporate actions or governance changes that may impact investors.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- HilleVax, Inc. (company) — Registrant
- June 23, 2025 (date) — Date of earliest event reported
- June 25, 2025 (date) — Date of report
- 001-41365 (company) — Commission File Number
- 321 Harrison Avenue, Suite 500, Boston, MA 02118 (address) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of HilleVax, Inc. security holders on June 23, 2025?
The filing does not specify the exact matters submitted for a vote; it only reports that such a submission occurred.
What was the outcome of the vote on June 23, 2025?
The filing does not disclose the results or outcome of the shareholder vote.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed on June 25, 2025.
What is HilleVax, Inc.'s principal executive office address?
HilleVax, Inc.'s principal executive offices are located at 321 Harrison Avenue, Suite 500, Boston, Massachusetts 02118.
What is HilleVax, Inc.'s Commission File Number?
HilleVax, Inc.'s Commission File Number is 001-41365.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding HilleVax, Inc..